<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375632</url>
  </required_header>
  <id_info>
    <org_study_id>FYU-981-013</org_study_id>
    <nct_id>NCT03375632</nct_id>
  </id_info>
  <brief_title>Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)</brief_title>
  <official_title>Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemic Outpatients With or Without Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fuji Yakuhin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mochida Pharmaceutical Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for
      14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male
      hyperuricemic outpatients with or without gout.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics (Amount of uric acid excreted in urine)</measure>
    <time_frame>2-week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Amount of uric acid excreted in urine)</measure>
    <time_frame>6-week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Amount of uric acid excreted in urine)</measure>
    <time_frame>10-week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Amount of uric acid excreted in urine)</measure>
    <time_frame>14-week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hyperuricemia With or Without Gout</condition>
  <arm_group>
    <arm_group_label>Uric acid-overproduction Type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Uric acid-underexcretion Type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FYU-981</intervention_name>
    <description>Oral daily dosing for 14 weeks</description>
    <arm_group_label>Uric acid-overproduction Type</arm_group_label>
    <arm_group_label>Uric acid-underexcretion Type</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum urate level:

               -  &gt;= 7.0mg/dL in patients with gouty nodule or with history of gout, or &gt;=8.0mg/dL
                  in patients with hypertension, diabetes or metabolic syndrome, or &gt;= 9.0mg/dL

          -  Disease type in the classification of hyperuricemia: Uric acid-overproduction type or
             Uric acid-underexcretion type

          -  Outpatients

        Exclusion Criteria:

          -  Gouty arthritis within 14 days before randomized allocation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuki Furuno</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kazuki Furuno</last_name>
    <phone>+81-3-3225-6332</phone>
    <email>kazuki.furuno@mochida.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mochida Investigational sites</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

